Singapore DNA sequencing is an umbrella term that includes both
Sangers and Non-Sangers method of sequencing. In the DNA sequencing process,
DNA is extracted, fragmented, and linked to adapters and primers for the
amplification reaction (PCR) for library construction. Further, sequencing of
the fragmented DNA is executed that furnishes a massive set of sequence data in
a very small duration. This data is interpreted and analyzed by clinicians,
researchers, scientists, and others through clinical, agricultural, forensic,
and other applications. For instance, DNA sequencing has helped researchers
identify desirable traits, which have led to resilient and productive livestock
and crops. The increase in usage and application of DNA sequencing is expected
to boost the Singapore market growth.
๐๐ฒ๐ ๐๐ฒ๐๐ฎ๐ถ๐น๐ฒ๐ฑ
๐๐๐ฉ๐จ๐ซ๐ญ
https://www.alliedmarketresearch.com/dna-sequencing-market
The major factors that drive the Singapore DNA sequencing
market are rise in technological advancements in DNA sequencing, growth in
collaborations & partnerships, and increase in genome mapping programs
globally. In addition, rise in investment in R&D enhances the demand for DNA
sequencing and thereby provides lucrative opportunities for the market growth.
However, accuracy & standardization concerns and ethical & legal
limitations associated with DNA sequencing restrain the Singapore market growth.
The consumables product segment occupies the highest share
in the Singapore DNA sequencing product market, owing to their sheer usage and need
throughout the sample preparation, library construction, and other
pre-requisite steps of DNA sequencing. The sequencing by synthesis technology
segment is anticipated to dominate the Singapore DNA sequencing market as most of
the widely-used DNA sequencing platforms utilize this technology in sequencing
protocols. This segment accounted for nearly two-fifths of the total share in
2017
Based on application, the biomarkers and cancer segment
dominates the market and the personalized medicine segment is expected to grow
at a CAGR of 26.7%. DNA sequencing possesses the potential to recognize a broad
spectrum of genetic differences and supplement the generation of potent biomarkers
in medicine and disease diagnostics. In addition, sequencing time, protocol
length, and declining cost of DNA sequencing make it an ideal technology for
biomarker discovery.
The Singapore major companies profiled in the report include Abbott
Laboratories, Agilent Technologies, Inc., Danaher Corporation (Beckman Coulter,
Inc.), F. Hoffmann-La Roche Ltd; Illumina, Inc., LI-COR Biosciences, Inc.,
Pacific Biosciences of California, Inc., Siemens AG, PerkinElmer Inc., and
Thermo Fisher Scientific, Inc. The other prominent players in the value chain
(but not included in the report) include Eurofins Scientific, Gatc Biotech AG,
Macrogen, Inc., Oxford Nanopore Technologies, Ltd., Bio-Rad Laboratories, Inc.,
DNASTAR, Inc., Biomatters Ltd., New England Biolabs, Inc., and Myriad Genetics,
Inc.
0 Comments